Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance

Genome-scale CRISPR-Cas9 Knockout Screening was applied to investigate novel targets in imatinib-resistant gastrointestinal stromal tumor (GIST). 20 genes and 2 miRNAs have been selected by total reads of sgRNA and sgRNA diversity, which has been further validated in imatinib-resistant GIST cells by...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jie, Wei, Jianchang, Yang, Ping, Zhang, Tong, Chen, Zhuanpeng, He, Feng, Wei, Fang, Chen, Huacui, Hu, He, Zhong, Junbin, Yang, Zhi, Cai, Wensong, Li, Wanglin, Wang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090611/
https://www.ncbi.nlm.nih.gov/pubmed/30103756
http://dx.doi.org/10.1186/s12943-018-0865-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090611/
https://www.ncbi.nlm.nih.gov/pubmed/30103756
http://dx.doi.org/10.1186/s12943-018-0865-2

Ejemplares similares